News: Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

70.00USD
17 Apr 2014
Price Change (% chg)

$0.72 (+1.04%)
Prev Close
$69.28
Open
$69.37
Day's High
$70.64
Day's Low
$69.09
Volume
17,548,425
Avg. Vol
15,720,398
52-wk High
$84.88
52-wk Low
$46.70

Search Stocks
Select another date:

Thu, Apr 17 2014

Photo

UnitedHealth: New hepatitis C drug costs far more than forecast

- UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was "multiple" times what it had expected.

UPDATE 4-UnitedHealth: New hepatitis C drug costs far more than forecast

April 17 - UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was "multiple" times what it had expected.

England agrees funding for Gilead hepatitis C drug

LONDON, April 17 - Health authorities in England have approved an 18.7 million pound ($31 million) investment to provide Gilead Sciences' controversial new hepatitis C pill Sovaldi for seriously ill patients.

Biotech stocks rout beginning to reveal pockets of value

NEW YORK - Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

UPDATE 4-J&J beats forecasts as sales of new drugs shine

(Adds J&J comment on weak medical device sales, updates shares)

Texas Medicaid holds off on proposed limits for Gilead hepatitis drug

- Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.

Texas Medicaid holds off on proposed limits for Gilead hepatitis drug

April 11 - Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.

Doctors welcome hepatitis C drug rivals, Gilead still leads

LOS ANGELES/LONDON - Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

Nasdaq drops 3 percent, worst day since November 2011

NEW YORK - The Nasdaq suffered its biggest drop in two-and-a-half years on Thursday after another sharp selloff in biotech and momentum names, including Gilead Sciences and TripAdvisor , increasing investor anxiety about a broader pullback. | Video

US STOCKS-Nasdaq marks worst day since Nov. 2011 as biotechs sink

* Nasdaq posts biggest daily percentage loss since Nov. 9, 2011

Select another date:
Search Stocks